Cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 18 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Cellectis uses the power of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering technologies, Cellectis’ goal is to create innovative products in multiple fields and with various target markets.
Cellectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
We are seeking for a highly motivated individual to join us as a Quality Control Director. The successful candidate will work as part of the Pharmaceutical Compliance team of Cellectis Paris and will be responsible for the set up and management of a new GMP testing facility in Paris, and for the recruitment and management of the associated new QC team.
He/She will be responsible for the supervision of QC strategy and testing on Cellectis GMP/High Quality Grade Raw and Starting Material (Plasmids, mRNA, Viral Vectors), ensuring compliance with regulatory requirements in EU, and US, accuracy, consistency across Cellectis family products and cost effectiveness.
He/She advises on and coordinates the QC activities related to the development and clinical investigation of Products, associated devices and laboratory equipment.
The Quality Control Director is also a crucial link between Cellectis GMP facility, subcontracted testing facilities and various stakeholders.